Cargando…
Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease
Parkinson disease (PD) is a neurodegenerative disease mainly characterized by the loss of nigral dopaminergic neurons in the substantia nigra pars compacta. Patients suffering from PD develop severe motor dysfunctions and a myriad of non-motor symptoms. The treatment mainly consists of increasing ce...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401573/ https://www.ncbi.nlm.nih.gov/pubmed/34451872 http://dx.doi.org/10.3390/ph14080775 |
_version_ | 1783745582864531456 |
---|---|
author | Holanda, Victor A. D. Didonet, Julia J. Costa, Manara B. B. do Nascimento Rangel, Adriano H. da Silva, Edilson D. Gavioli, Elaine C. |
author_facet | Holanda, Victor A. D. Didonet, Julia J. Costa, Manara B. B. do Nascimento Rangel, Adriano H. da Silva, Edilson D. Gavioli, Elaine C. |
author_sort | Holanda, Victor A. D. |
collection | PubMed |
description | Parkinson disease (PD) is a neurodegenerative disease mainly characterized by the loss of nigral dopaminergic neurons in the substantia nigra pars compacta. Patients suffering from PD develop severe motor dysfunctions and a myriad of non-motor symptoms. The treatment mainly consists of increasing central dopaminergic neurotransmission and alleviating motor symptoms, thus promoting severe side effects without modifying the disease’s progress. A growing body of evidence suggests a close relationship between neuropeptide S (NPS) and its receptor (NPSR) system in PD: (i) double immunofluorescence labeling studies showed that NPSR is expressed in the nigral tyrosine hydroxylase (TH)-positive neurons; (ii) central administration of NPS increases spontaneous locomotion in naïve rodents; (iii) central administration of NPS ameliorates motor and nonmotor dysfunctions in animal models of PD; (iv) microdialysis studies showed that NPS stimulates dopamine release in naïve and parkinsonian rodents; (v) central injection of NPS decreases oxidative damage to proteins and lipids in the rodent brain; and, (vi) 7 days of central administration of NPS protects from the progressive loss of nigral TH-positive cells in parkinsonian rats. Taken together, the NPS/NPSR system seems to be an emerging therapeutic strategy for alleviating motor and non-motor dysfunctions of PD and, possibly, for slowing disease progress. |
format | Online Article Text |
id | pubmed-8401573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84015732021-08-29 Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease Holanda, Victor A. D. Didonet, Julia J. Costa, Manara B. B. do Nascimento Rangel, Adriano H. da Silva, Edilson D. Gavioli, Elaine C. Pharmaceuticals (Basel) Review Parkinson disease (PD) is a neurodegenerative disease mainly characterized by the loss of nigral dopaminergic neurons in the substantia nigra pars compacta. Patients suffering from PD develop severe motor dysfunctions and a myriad of non-motor symptoms. The treatment mainly consists of increasing central dopaminergic neurotransmission and alleviating motor symptoms, thus promoting severe side effects without modifying the disease’s progress. A growing body of evidence suggests a close relationship between neuropeptide S (NPS) and its receptor (NPSR) system in PD: (i) double immunofluorescence labeling studies showed that NPSR is expressed in the nigral tyrosine hydroxylase (TH)-positive neurons; (ii) central administration of NPS increases spontaneous locomotion in naïve rodents; (iii) central administration of NPS ameliorates motor and nonmotor dysfunctions in animal models of PD; (iv) microdialysis studies showed that NPS stimulates dopamine release in naïve and parkinsonian rodents; (v) central injection of NPS decreases oxidative damage to proteins and lipids in the rodent brain; and, (vi) 7 days of central administration of NPS protects from the progressive loss of nigral TH-positive cells in parkinsonian rats. Taken together, the NPS/NPSR system seems to be an emerging therapeutic strategy for alleviating motor and non-motor dysfunctions of PD and, possibly, for slowing disease progress. MDPI 2021-08-06 /pmc/articles/PMC8401573/ /pubmed/34451872 http://dx.doi.org/10.3390/ph14080775 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Holanda, Victor A. D. Didonet, Julia J. Costa, Manara B. B. do Nascimento Rangel, Adriano H. da Silva, Edilson D. Gavioli, Elaine C. Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease |
title | Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease |
title_full | Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease |
title_fullStr | Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease |
title_full_unstemmed | Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease |
title_short | Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease |
title_sort | neuropeptide s receptor as an innovative therapeutic target for parkinson disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401573/ https://www.ncbi.nlm.nih.gov/pubmed/34451872 http://dx.doi.org/10.3390/ph14080775 |
work_keys_str_mv | AT holandavictorad neuropeptidesreceptorasaninnovativetherapeutictargetforparkinsondisease AT didonetjuliaj neuropeptidesreceptorasaninnovativetherapeutictargetforparkinsondisease AT costamanarabb neuropeptidesreceptorasaninnovativetherapeutictargetforparkinsondisease AT donascimentorangeladrianoh neuropeptidesreceptorasaninnovativetherapeutictargetforparkinsondisease AT dasilvaedilsond neuropeptidesreceptorasaninnovativetherapeutictargetforparkinsondisease AT gaviolielainec neuropeptidesreceptorasaninnovativetherapeutictargetforparkinsondisease |